Magenta Therapeutics, Inc. (MGTA): Price and Financial Metrics
GET POWR RATINGS... FREE!
MGTA Stock Price Chart Interactive Chart >
MGTA Price/Volume Stats
|Current price||$1.16||52-week high||$6.44|
|Prev. close||$1.16||52-week low||$0.92|
|Day high||$1.30||Avg. volume||254,089|
|50-day MA||$1.31||Dividend yield||N/A|
|200-day MA||$1.80||Market Cap||70.24M|
Magenta Therapeutics, Inc. (MGTA) Company Bio
Magenta Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing medicines to bring the curative power of bone marrow transplant to patients. It is developing C100, C200, and C300 targeted antibody-drug conjugates for transplant conditioning; MGTA-145, a stem cell mobilization product candidate to control stem cell mobilization; MGTA-456, an allogeneic stem cell therapy to control stem cell growth; E478, a small molecule aryl hydrocarbon receptor antagonist for the expansion of gene-modified stem cells; and G100, an ADC program to prevent acute graft and host diseases. The company was formerly known as HSCTCo Therapeutics, Inc. and changed its name to Magenta Therapeutics, Inc. in February 2016. The company was founded in 2015 and is based in Cambridge, Massachusetts.
Most Popular Stories View All
MGTA Latest News Stream
|Loading, please wait...|
MGTA Latest Social Stream
View Full MGTA Social Stream
Latest MGTA News From Around the Web
Below are the latest news stories about MAGENTA THERAPEUTICS INC that investors may wish to consider to help them evaluate MGTA as an investment opportunity.
Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting
– Oral presentation of MGTA-117 Phase 1/2 dose escalation clinical trial abstract, with additional clinical data supporting proof-of-mechanism – – Poster presentation of data from a MGTA-117 non-human primate study that has provided predictive modeling of biologic activity in the ongoing Phase 1/2 dose escalation clinical trial – – Poster presentation of MGTA-145 “trial-in-progress” abstract describing the clinical trial design for mobilization and collection of stem cells from patients with sic
– New clinical results from ongoing MGTA-117 Phase 1/2 clinical trial support earlier observations of target binding, target cell depletion, rapid drug clearance and a favorable tolerability profile; clinical trial has progressed into the third dose escalation cohort; oral presentation of clinical data will be given at the 2022 American Society of Hematology (ASH) meeting in December 2022 – – CD45 antibody-drug conjugate (ADC) dose-ranging toxicology study successfully completed; IND-enabling st
CAMBRIDGE, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Magenta Therapeutics (Nasdaq: MGTA), a clinical-stage biotechnology company developing novel medicines designed to bring the curative power of stem cell transplant to more patients, today announced that the company will present at the Credit Suisse 31st Annual Healthcare Conference being held November 7-10, 2022. The webcast of Magenta's presentation will be accessible at 8:00am Pacific Time on Tuesday, November 8, 2022 on the Magenta Therapeut
We can readily understand why investors are attracted to unprofitable companies. For example, although...
In this article, we discuss the 15 stocks Australian billionaire Kerr Neilson is selling. If you want to skip our analysis of Neilson’s history and investment philosophy, go directly to Australian Billionaire Kerr Neilson is Selling These 15 Stocks. Kerr Neilson is a billionaire investor who co-founded Platinum Asset Management with Andrew Clifford nearly 28 […]
MGTA Price Returns